Most Favored Nation and What's Next from AVBCC Value-Based Voices

AVBCC Value-Based Voices

Rachael

Episodes

About

Reviews

Promote

Most Favored Nation and What's Next

33 minutes Posted Apr 14, 2026 at 1:00 pm.

Introduction

Historical background of the Most Favored Nation policy

Details on the Globe and Guard models proposed by CMS

PCMA’s position on Guard and its impact on drug cost negotiations

Nick Ferreyros from COA discusses Globe’s effects on community oncology

The technical design and provider implications of Guard’s rebate mechanism

Policy and legal issues surrounding importing international prices and value metrics

Public comments and stakeholder concerns about the models’ scope and impact

Potential future legal challenges and legislative actions regarding MFN policies

Community oncology’s response to the models and their administrative burdens

Broader healthcare system considerations and international comparisons

The importance of quality-adjusted life years and legislative exclusions

Expert opinions on the likelihood of litigation and the role of CMMI

Political developments and the prospects of codifying MFN policies into law

The implications for physician reimbursement and outpatient oncology practices

Predictions on congressional action and the near-term future of MFN legislation

The legal landscape: chances of success in upcoming litigation and oversight concerns

0:00

33:49

Download MP3

Share at current time

Show notes

Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America? In this episode of Value-Based Voices, Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., dives into the evolving landscape of drug pricing reforms, unlocking why policies like the Most Favored Nation (MFN) and the Global Benchmark could reshape how medicines reach patients, providers, and payers. You’ll discover ...

← See all 6 episodes of AVBCC Value-Based Voices